Henderson B W, Bellnier D A, Greco W R, Sharma A, Pandey R K, Vaughan L A, Weishaupt K R, Dougherty T J
Department of Radiation Biology, Roswell Park Cancer Institute, Buffalo, New York 14263, USA.
Cancer Res. 1997 Sep 15;57(18):4000-7.
An in vivo quantitative structure-activity relationship (QSAR) study was carried out on a congeneric series of pyropheophorbide photosensitizers to identify structural features critical for their antitumor activity in photodynamic therapy (PDT). The structural elements evaluated in this study include the length and shape (alkyl, alkenyl, cyclic, and secondary analogs) of the ether side chain. C3H mice, harboring the radiation-induced fibrosarcoma tumor model, were used to study three biological response endpoints: tumor growth delay, tumor cell lethality, and vascular perfusion. All three endpoints revealed highly similar QSAR patterns that constituted a function of the alkyl ether chain length and drug lipophilicity, which is defined as the log of the octanol:water partition coefficient (log P). When the illumination of tumor, tumor cells, or cutaneous vasculature occurred 24 h after sensitizer administration, activities were minimal with analogs of log P < or = 5, increased dramatically between log P of 5-6, and peaked between log P of 5.6-6.6. Activities declined gradually with higher log P. The lack of activity of the least-lipophilic analogs was explained in large part by their poor biodistribution characteristics, which yielded negligible tumor and plasma drug levels at the time of treatment with light. The progressively lower potencies of the most lipophilic analogs cannot be explained through the overall tumor and plasma pharmacokinetics of photosensitizer because tumor and plasma concentrations progressively increased with lipophilicity. When compensated for differences in tumor photosensitizer concentration, the 1-hexyl derivative (optimal lipophilicity) was 5-fold more potent than the 1-dodecyl derivative (more lipophilic) and 3-fold more potent than the 1-pentyl analog (less lipophilic), indicating that, in addition to the overall tumor pharmacokinetics, pharmacodynamic factors may influence PDT activity. Drug lipophilicity was highly predictive for photodynamic activity. QSAR modeling revealed that direct antitumor effects and vascular PDT effects may be governed by common mechanisms, and that the mere association of high levels of photosensitizer in the tumor tissue is not sufficient for optimal PDT efficiency.
对一系列同类的焦脱镁叶绿酸光敏剂进行了体内定量构效关系(QSAR)研究,以确定在光动力疗法(PDT)中对其抗肿瘤活性至关重要的结构特征。本研究评估的结构要素包括醚侧链的长度和形状(烷基、烯基、环状和二级类似物)。使用携带辐射诱导纤维肉瘤肿瘤模型的C3H小鼠来研究三个生物学反应终点:肿瘤生长延迟、肿瘤细胞致死率和血管灌注。所有这三个终点都显示出高度相似的QSAR模式,这些模式构成了烷基醚链长度和药物亲脂性的函数,药物亲脂性定义为辛醇:水分配系数的对数(log P)。当在给予敏化剂24小时后对肿瘤、肿瘤细胞或皮肤血管进行照射时,log P≤5的类似物活性最小,在log P为5 - 6之间急剧增加,并在log P为5.6 - 6.6之间达到峰值。随着log P值更高,活性逐渐下降。亲脂性最低的类似物缺乏活性,这在很大程度上是由于其不良的生物分布特征,在用光治疗时肿瘤和血浆药物水平可忽略不计。亲脂性最高的类似物效力逐渐降低,无法通过光敏剂的整体肿瘤和血浆药代动力学来解释,因为肿瘤和血浆浓度随着亲脂性而逐渐增加。当补偿肿瘤光敏剂浓度的差异时,1 - 己基衍生物(最佳亲脂性)的效力比1 - 十二烷基衍生物(亲脂性更强)高5倍,比1 - 戊基类似物(亲脂性更弱)高3倍,这表明除了整体肿瘤药代动力学外,药效学因素可能影响PDT活性。药物亲脂性对光动力活性具有高度预测性。QSAR建模表明,直接抗肿瘤作用和血管PDT作用可能受共同机制支配,并且仅仅肿瘤组织中高水平光敏剂的存在不足以实现最佳的PDT效率。